As of today in the United States, cannabis is legal in 33 states for medical purposes and 11 states have adult-use laws on the books. Cannabis is also still considered a Schedule 1 drug under the federal government’s outdated Controlled Substances Act, placing cannabis alongside some very dangerous drugs and classifying it as having no medical value. However, there is a plethora of research evidence that proves the contrary.
Therefore, it should come as no surprise that lawmakers from the U.S. House of Representatives are putting increased pressure on regulators under President Trump’s administration to change federal cannabis laws.
During Wednesday’s House Energy and Commerce Health Subcommittee hearing, the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), and the National Institute on Drug Abuse (NIDA) were pressed by bipartisan lawmakers about the restrictions around studying cannabis products and hemp-based cannabidiol (CBD).